Article
Public (all visitors)
Data on Gilead drug raises hopes in pandemic fight, Fauci calls it “highly significant” — Reuters
APPLE
2020
The top U.S. infectious disease official said Gilead Sciences Inc's experimental antiviral drug remdesivir will become the standard of care for COVID-19 after early results from a key clinical trial on Wednesday showed it helped patients recover more quickly from the illness...
Show More
Curated by
FoundryBase
Visibility
Public (all visitors)
Saved in
1 chunk
Kind
Article
Response
Browse more
View All ArticlesAdjacent discoveries
Keep moving through nearby material.
Related resources
With chunks in common.
Remdesivir has ‘little or no effect’ in reducing coronavirus deaths, WHO says
2020
Appears in 1 shared chunk
The ‘very, very bad look’ of remdesivir, the first FDA-approved COVID-19 drug
2020
Appears in 1 shared chunk
More related content
With shared categories.
FDA grants historic approval to Alzheimer’s drug designed to slow cognitive decline
2021
Shares 12 topic signals
The story of mRNA: How a once-dismissed idea became a leading technology in the Covid vaccine race
2020
Shares 12 topic signals
Oxford University’s COVID-19 vaccine shows high efficacy, and is cheaper to make and easier to store
2020
Shares 12 topic signals
Dozens of COVID-19 vaccines are in development. Here are the ones to follow - National Geographic
2020
Shares 12 topic signals
The ‘very, very bad look’ of remdesivir, the first FDA-approved COVID-19 drug
2020
Shares 12 topic signals
Nature: The race to make COVID antibody therapies cheaper and more potent (Oct. 2020)
2020
Shares 12 topic signals
Remdesivir has ‘little or no effect’ in reducing coronavirus deaths, WHO says
2020
Shares 12 topic signals
U.S. pauses Eli Lilly's trial of a coronavirus antibody treatment over safety concerns
2020
Shares 12 topic signals
Contribute to FoundryBase
Found something worth adding?
Sign in to suggest resources and start building your own collection.